Seikagaku Corporation (4548.T)

882,00 -7,00 (-0,79%) Ab 10:27AM JST. Markt geöffnet.

Seikagaku Corporation

Marunouchi Center Building
10th Floor 6-1, Marunouchi 1-chome Chiyoda-ku
Tokyo 100-0005
Japan
81 3 5220 8950
https://www.seikagaku.co.jp

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 990

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kenji Mizutani	President, CEO, Executive VP & Representative Director	N/A	N/A	1948
Kazushi Takeda	Executive Vice President of HR, F&A and Corporate Staff	N/A	N/A	N/A
Yuji Shimojima	Executive Vice President of Quality Compliance & Medical Affairs	N/A	N/A	N/A
Ms. Mikako Torii	Executive VP, Head of Corporate Staff and Audit & Supervisory Board Member	N/A	N/A	1964
Mr. Toshiyuki Okada	Managing Executive Officer & Director	N/A	N/A	1960
Mr. Yosuke Funakoshi	Senior Executive Officer, GM of Research & Development and Director	N/A	N/A	1965
Masayuki Ito	Executive VP & Head of Production	N/A	N/A	N/A
Ryoji Tomokiyo	Executive Vice President of Business Development & Marketing	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in JPY.

Beschreibung

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally.The company operates in two segments, Pharmaceuticals and LAL Business. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for knee osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

Corporate Governance

Seikagaku Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.